Navigation Links
Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
Date:5/17/2012

SAN DIEGO, May 17, 2012 /PRNewswire/ -- Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120 (AAV2-neurturin).  Raymond T. Bartus, Ph.D., Ceregene's chief scientific officer and executive vice president, was invited to give a presentation entitled "The Development of AAV2-neurturin (CERE-120) for Parkinson's Disease: A Review of the Challenges and Translation Issues Confronted During the Course of Establishing 'Clinical Proof of Concept,'" at the annual meeting of the American Society for Gene and Cell Therapy during the Clinical Trials I Symposium on Thursday, May 17, 2012 in Philadelphia, PA.  CERE-120 is a viral vector engineered to deliver the nervous system growth factor neurturin (NRTN), which has the ability to rejuvenate degenerating dopamine-producing neurons, restoring function and keeping them alive.  NRTN has been shown to safely protect and restore damaged nigrostriatal nerves in animal models of Parkinson's disease and appears safe in humans tested in four Ceregene-sponsored clinical studies enrolling a total of 120 patients, 80 of whom were administered CERE-120.  A previous double blind-controlled human study demonstrated clinical benefit on several motor and Quality of Life (QOL) endpoints 12 and 18 months following CERE-120 delivery (with no measure favoring sham) and established clinical proof of concept in humans. 

Dr. Bartus will present histological evaluation of autopsy tissue from subjects administered CERE-120 to the brain who later died of unrelated causes.  Analysis of brains from Parkinson's subjects 1.5 and 3 months post-CERE-120 treatment revealed NRTN expression in the targeted putaminal regio
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
3. Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinsons Disease
4. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 1 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... obesity, today announced that the U.S. Food and Drug ... Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its ... is based on a substantial body of evidence gathered ...
... , IRVINE, Calif. , June 1 Cardiogenesis ... present at the Noble Financial Sixth Annual Equity Conference - ONTRACK ... Hollywood, Florida .  Executive Chairman Paul J. McCormick will ... at 5:00 pm Eastern Time ( 2:00 pm ...
Cached Medicine Technology:Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 2Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 3Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... cancers, especially leukemia, have improved greatly in the ... seem to face many health,and lifestyle challenges as ... and treatment methods, many continue to struggle with ... of life, according to a,study prepublished online in ...
... March 31 Hillenbrand,Industries, Inc. (NYSE: HB ) ... previously announced cash tender offer to purchase any,and all ... (CUSIP No.,431573AD6). The tender offer was made pursuant to ... to Purchase") and the related Letter of,Transmittal, which set ...
... 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... under which it may sell up to $50,million of ... a,24-month period. Alexza is not obligated to utilize any ... into and consummate other equity and,debt financing transactions., ...
... a Solid Foundation for Marriage and Family, ... offering an innovative program, "Supporting Healthy Marriage" to ... The purpose,of the program, administered by University Behavioral ... build a solid foundation,for marriage and family through ...
... to Consulting Addresses Fears That Lawyers Have That, ... Accurately Describes The Business, WASHINGTON, March 31 ... announced it is,becoming the first in the nation ... attorney. It had previously been the first in ...
... reduce lead dust during renovations , , MONDAY, March ... issued new rules designed to protect children from ... to homes and buildings. , Starting in ... standards" that are designed to reduce potential exposure ...
Cached Medicine News:Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 2Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 3Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 4Health News:Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 2Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 4Health News:'Supporting Healthy Marriage' Program Offered by Montefiore 2Health News:Leventhal Weight Loss Incorporated Becomes First in the Nation Executive Weight Loss Consulting Service for Attorneys by an Attorney 2Health News:New Rule Seeks to Protect Kids From Lead Paint 2
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
250L...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: